Soleno Therapeutics’ (SLNO) Investor Sentiment Subdued Amid Growth Concerns

2 hours ago 1

Soumya Eswaran

Thu, April 2, 2026 astatine 8:39 AM CDT 3 min read

TimesSquare Capital Management, an equity concern absorption company, released its “U.S. Small Cap Growth Strategy” fourth-quarter 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. The strategy returned 3.70% (gross) and 3.45% (net) successful the 4th fourth compared to a 1.22% instrumentality for the Russell 2000 Growth Index. In 2025, the strategy returned 6.91% (gross) and 5.85% (net) compared to 13.01% for the index. Global equity markets ended the 4th connected a affirmative note, with Europe leading, followed by Emerging Markets. In astir markets, ample caps outperformed tiny caps. The commercialized truce betwixt the United States and China was prolonged for an further year, but planetary geopolitical concerns, whether related to tariffs oregon not, persisted. Third-quarter GDP exceeded expectations, but user caution persists amid ongoing labor-market softening, influencing the Fed’s determination connected interest-rate cuts. Please reappraisal the Strategy’s apical 5 holdings to summation insights into their cardinal selections for 2025.

In its fourth-quarter 2025 capitalist letter, TimesSquare Capital U.S. Small Cap Growth Strategy highlighted stocks similar Soleno Therapeutics, Inc. (NASDAQ:SLNO). Soleno Therapeutics, Inc. (NASDAQ:SLNO) is simply a biopharmaceutical institution that develops and commercializes caller therapeutics for the attraction of uncommon diseases. On April 1, 2026, Soleno Therapeutics, Inc. (NASDAQ:SLNO) closed astatine $36.99 per share. One-month instrumentality of Soleno Therapeutics, Inc. (NASDAQ:SLNO) was -4.10%, and its shares mislaid 48.74% implicit the past 52 weeks. Soleno Therapeutics, Inc. (NASDAQ:SLNO) has a marketplace capitalization of $1.987 billion.

TimesSquare Capital U.S. Small Cap Growth Strategy stated the pursuing regarding Soleno Therapeutics, Inc. (NASDAQ:SLNO) successful its 4th fourth 2025 capitalist letter:

"Our preferences among Health Care stocks are those companies providing caller therapies for unmet needs that bid premium pricing, oregon specialized work providers. We closed our presumption successful biopharma developer Soleno Therapeutics, Inc. (NASDAQ:SLNO), which recorded a -34% diminution portion held wrong the portfolio this quarter. Even though the company’s Vykat XR stands arsenic the sole approved therapy for hyperphagia successful Prader-Willi Syndrome (PWS), capitalist sentiment remains subdued owed to ongoing concerns regarding the maturation trajectory."

Why Soleno Therapeutics Inc. (SLNO) Went Up Last Week?

Soleno Therapeutics, Inc. (NASDAQ:SLNO) is not connected our database of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 57 hedge money portfolios held Soleno Therapeutics, Inc. (NASDAQ:SLNO) astatine the extremity of the 4th quarter, compared to 58 successful the erstwhile quarter. While we admit the imaginable of Soleno Therapeutics, Inc. (NASDAQ:SLNO) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

Read Entire Article